• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Oncotarget: Researchers identify novel therapeutic strategy for drug-resistant thyroid cancers

Bioengineer by Bioengineer
October 18, 2017
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Credit: Oncotarget

ORCHARD PARK, New York – (Oct. 18, 2017) – Perhaps the only thing more devastating than being diagnosed with cancer is to find out after a period of remission that the cancer has become drug-resistant and progressed to an incurable state. This is the unfortunate fate for many patients with papillary thyroid carcinoma (PTC), the most common form of thyroid cancer, who are treated with the drug vemurafenib. However, new findings by a Harvard Medical School team suggest that palbociclib, a drug that is FDA-approved to treat advanced breast cancer, may be able to overcome vemurafenib resistance in PTC. Their results were published today on the cover for Oncotarget.

The genetic hallmark of PTC is a specific mutation in the BRAF gene. Patients presenting with the "BRAFV600E" mutation, as it is referred to, are often treated with drugs like vemurafenib, which selectively target this mutation. However, most patients that initially respond to treatment eventually develop drug resistance, allowing the cancer to grow and spread.

"Our findings suggest for the first time that a combination drug therapy using vemurafenib and palbociclib represents a novel therapeutic strategy to treat PTC," said lead author of the study Carmelo Nucera M.D., Ph.D., an assistant professor at Harvard Medical School.

Previous research by this team had shown that in lab-grown vemurafenib-resistant thyroid cancer cells, loss of the P16 gene – which prevents cells from dividing too often – may be linked to the ability of the cancer cells to continue growing even when treated with vemurafenib.

One way P16 controls cell division is by preventing the formation of a protein complex called CDK4/6, which is required for DNA to replicate inside cells. Nucera and his team wondered whether they could prevent treatment resistance by targeting the CDK4/6 complex, in effect mimicking what P16 might do. They identified palbociclib, a CDK4/6 inhibitor that was already FDA approved to treat advanced breast cancer, as a potential candidate.

When the researchers treated cells from vemurafenib-resistant, BRAFV600E-positive PTC patients with a combination of vemurafenib and palbociclib, they found that drugs acted synergistically to induce stronger cell death than when either drug was used alone.

Interestingly, in the course of the study, the researchers also identified that the cells harbored another deleterious genetic aberration that they propose may be a novel secondary mechanism of treatment resistance in cells that are already vemurafenib-resistant. Furthermore, they confirmed that that combined therapy with vemurafenib plus palbociclib results in a very efficient strategy to target PTC cells either with primary or secondary resistance.

"Our results support the proof of concept that this combined therapy can be tested in a clinical trial of patients with metastatic thyroid cancer," said Nucera.

###

A video interview with the corresponding author and an audio version of this research article is also available online.

About Oncotarget

Oncotarget is twice-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology such as Aging, Immunology and Microbiology, Autophagy, Pathology and Chromosomes and more. Oncotarget is published by Rapamycin Press, the publishing division of Impact Journals LLC.

Media Contact

Ryan James Jessup
[email protected]
202-638-9720

Original Source

http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=news&op=press&item=20171018 http://dx.doi.org/10.18632/oncotarget.21262

Share12Tweet7Share2ShareShareShare1

Related Posts

blank

Revolutionizing Multi-Sample Single-Cell RNA-seq Detection

October 6, 2025
blank

Revolutionizing Alkaloid Structural Analysis with an Innovative Metal–Organic Framework

October 6, 2025

Ant-Sheltered Tardigrades: A Unique Survival Strategy

October 6, 2025

Introducing E2E: A User-Friendly R Package for Building Ensemble Models with Ease

October 6, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    95 shares
    Share 38 Tweet 24
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    93 shares
    Share 37 Tweet 23
  • New Insights Suggest ALS May Be an Autoimmune Disease

    71 shares
    Share 28 Tweet 18
  • Ohio State Study Reveals Protein Quality Control Breakdown as Key Factor in Cancer Immunotherapy Failure

    71 shares
    Share 28 Tweet 18

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Boosting Cobalamin Production from Cashew Apple Waste

Curcumin Eases Symptoms in Hand Osteoarthritis: Study

Boosting Blockchain Audit Privacy with Hybrid Encryption

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 63 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.